通过提高分泌粘素合成,乌罗立A介导的肠道屏障功能的增强
Takeshi Yasuda1, Tomohisa Takagi2,3, Kohei Asaeda1
1Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan.
Scientific reports
|July 8, 2024
概括
乌罗立A通过Nrf2和AhR通路促进粘素2的表达,从而增强肠道粘液的产生. 这加强了肠道屏障,缓解了结肠炎.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 微生物组研究 微生物组研究
背景情况:
- 肠道粘液层对于天生的免疫力和肠道屏障功能至关重要.
- 肠道细菌的代谢物乌罗立A (Uro A) 对粘素的产生有不明确的影响.
- 了解Uro A的作用是探索其对肠道健康的治疗潜力的关键.
研究的目的:
- 调查乌罗立A对结肠粘素产生的保护作用.
- 阐明分子机制,特别是Nrf2和AhR通路的作用,这就是Uro A对粘液分泌的影响的基础.
- 评估Uro A在维持肠道屏障完整性和减轻大肠炎方面的有效性.
主要方法:
- 在体内研究使用野生类型和Nrf2缺乏的小鼠,以及AhR抗剂治疗.
- 用LS174T粘素生成细胞进行体外测定.
- 结肠粘液厚度的评估,粘素2表达,紧密结合完整性和粘膜透性 (FITC-dextran测定).
- 对硫酸 (DSS) 诱导的大肠炎和肠道微生物群分析的评估.
主要成果:
- 乌罗立A通过上调粘素2的表达,显著加厚小鼠的结肠粘液.
- 这种效应取决于核因素红色素2相关因子2 (Nrf2) 和酸受体 (AhR) 信号通路.
- 乌罗A降低了粘膜的透性,缓解了DSS诱导的大肠炎,并增加了有益的短链脂肪酸产生细菌.
结论:
- 乌罗立A可以增强肠道粘液分泌和屏障功能.
- 该机制涉及Nrf2和AhR信号通路的激活,导致粘素的产量增加.
- 乌罗A显示出作为维持肠道健康和治疗炎症状况的治疗剂的潜力.
相关概念视频
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
365
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
365
Mucosal Barrier of the Stomach
612
The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
612
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
435
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
435
Drugs for Treatment of Constipation-Predominant IBS
154
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
154
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
395
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
395
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
193
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
193


